Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.66 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | GFER | P55789 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | YWHAG | P61981 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | ST14 | Q9Y5Y6 | 2/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28845372 | 0.98 | NPC1 (0.69) | NPC1KEAP1MAPTGFERKDM4E | |
| SCHEMBL3654065 | 0.81 | NPC1 (0.96) | NPC1KEAP1MAPTGFERKDM4E | |
| SCHEMBL31565663 | 0.81 | NPC1 (0.96) | NPC1KEAP1MAPTGFERKDM4E | |
| SCHEMBL1740547 | 0.81 | NPC1 (0.66) | NPC1KEAP1MAPTGFERKDM4E | |
| SCHEMBL10675363 | 0.79 | NPC1 (0.59) | NPC1KEAP1MAPTMEN1KMT2A | |
| SCHEMBL605593 | 0.79 | NPC1 (1.00) | NPC1KEAP1MAPTGFERKDM4E | |
| SCHEMBL3083169 | 0.79 | NPC1 (1.00) | NPC1KEAP1MAPTGFERKDM4E | |
| SCHEMBL27566321 | 0.78 | NPC1 (0.41) | NPC1MAPTKDM4EMEN1ALOX15 | |
| SCHEMBL17009548 | 0.77 | NPC1 (0.89) | NPC1KEAP1MAPTGFERKDM4E | |
| SCHEMBL7328877 | 0.76 | NOTUM (0.55) | NPC1KDM4EMEN1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1810693-A2 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | Shering Corporation (US) | 2007-07-25 | — | — | EP | claimed |
| EP-1353694-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS | Schering Corporation (US) | 2003-10-22 | — | — | EP | claimed |
| US-20020147184-A1 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | SCHERING CORPORATION | 2002-10-10 | — | — | US | claimed |
| WO-2002058734-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | claimed |
| EP-3355890-B1 | HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2021-11-10 | — | — | EP | disclosed |
| US-8623873-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2014-01-07 | — | — | US | disclosed |
| EP-1810971-B1 | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia | MERCK SHARP & DOHME (US) | 2013-12-25 | — | — | EP | disclosed |
| EP-1606287-B1 | SUBSTITUTED AZETIDINONE COMPOUNDS, FORMULATIONS AND USES THEREOF FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | MERCK SHARP & DOHME (US) | 2013-10-02 | — | — | EP | disclosed |
| EP-1819684-B1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | INTERVET INT BV (NL) | 2013-08-07 | — | — | EP | disclosed |
| US-20130072468-A1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | GILBERT ERIC J (US) | 2013-03-21 | — | — | US | disclosed |
| EP-2548874-A2 | Substituted piperazines as CB1 antagonists | Intervet International B.V. (NL) | 2013-01-23 | — | — | EP | disclosed |
| US-8236805-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2012-08-07 | — | — | US | disclosed |
| WO-2002058732-A2 | COMBINATIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) ACTIVATOR(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| US-6057342-A | INHIBITORS OF TRYPSIN-LIKE SERINE PROTEASE ENZYMES, ESPECIALLY FACTOR XA, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME AS ANTICOAGULANT AGENTS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISORDERS | DUPONT PHARMACEUTICAL CO. (US) | 2000-05-02 | — | — | US | disclosed |
| US-6057342-A | INHIBITORS OF TRYPSIN-LIKE SERINE PROTEASE ENZYMES, ESPECIALLY FACTOR XA, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME AS ANTICOAGULANT AGENTS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISORDERS | DUPONT PHARMACEUTICAL CO. (US) | 2000-05-02 | — | — | US | disclosed |
| US-6057342-A | INHIBITORS OF TRYPSIN-LIKE SERINE PROTEASE ENZYMES, ESPECIALLY FACTOR XA, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME, AND METHODS OF USING THE SAME AS ANTICOAGULANT AGENTS FOR TREATMENT AND PREVENTION OF THROMBOEMBOLIC DISORDERS | DUPONT PHARMACEUTICAL CO. (US) | 2000-05-02 | — | — | US | disclosed |
| EP-0934265-A1 | AMIDINOPHENYL-PYRROLIDINES, -PYRROLINES, AND -ISOXAZOLIDINES AND DERIVATIVES THEREOF | Du Pont Pharmaceuticals Company (US) | 1999-08-11 | — | — | EP | disclosed |
| EP-0934265-A1 | AMIDINOPHENYL-PYRROLIDINES, -PYRROLINES, AND -ISOXAZOLIDINES AND DERIVATIVES THEREOF | Du Pont Pharmaceuticals Company (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998006694-A1 | AMIDINOPHENYL-PYRROLIDINES, -PYRROLINES, AND -ISOXAZOLIDINES AND DERIVATIVES THEREOF | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-02-19 | — | — | WO | disclosed |
| WO-1998006694-A1 | AMIDINOPHENYL-PYRROLIDINES, -PYRROLINES, AND -ISOXAZOLIDINES AND DERIVATIVES THEREOF | DU PONT PHARMACEUTICALS COMPANY (US) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072468-A1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | CNR1, CNR2, GPR119 | NPC1 589/4885KEAP1 1929/4885MAPT 1481/4885 |
| US-20020147184-A1 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | APOB, FABP2, CYP46A1 | NPC1 24/4885KEAP1 1338/4885MAPT 3868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.